1247. Dalbavancin in Osteomyelitis and Joint Infections: An Analysis From an Observational, Multicenter, Retrospective Cohort Study of the Real-World Use in Adult Patients

BACKGROUND: Dalbavancin (DAL) is approved in the United States (US) and Europe for acute bacterial skin and skin structure infections and exhibits broad spectrum activity against clinically important Gram-positive pathogens including methicillin-sensitive and methicillin-resistant Staphylococcus aur...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaz, Julia Garcia, McGregor, Jennifer, Ramani, Anathakrishnan, Lock, John, Golan, Yoav, Gonzalez, Pedro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776746/
http://dx.doi.org/10.1093/ofid/ofaa439.1431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776746/
http://dx.doi.org/10.1093/ofid/ofaa439.1431

Ejemplares similares